[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342377-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342377-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","implementation-status-of-pharmacological-studies-in-the-development-of-orphan-drugs","Implementation status of pharmacological studies in the development of orphan drugs","","Orphan drug development is challenging due to incomplete understanding of pathophysiology and limited availability of animal models, while existing FDA guidance and EMA guideline describe non-clinical studies without specifying animal species or study designs. A review of Japan-approved orphan drugs from 2010–2019 assessed nonclinical efficacy evaluation methods and outcomes. The study analyzed 184 orphan drugs and identified flexible, disease-characteristic approaches using patient-derived cells, alternative models, and biomarker-based endpoints.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/implementation-status-of-pharmacological-studies-in-the-development-of-orphan-drugs/342377/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/implementation-status-of-pharmacological-studies-in-the-development-of-orphan-drugs/342377.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is developing orphan drugs difficult in nonclinical and clinical stages?","Question",{"text":63,"@type":64},"Nonclinical and clinical development is difficult because disease mechanisms are not well understood and established animal models are often absent. Existing guidance also lacks specific details such as animal species and study design.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many orphan drugs were investigated, and what was the study period?",{"text":68,"@type":64},"The review investigated 184 orphan drugs approved in Japan, covering January 2010 to December 2019.",{"name":70,"@type":61,"acceptedAnswer":71},"What approaches were used to evaluate nonclinical efficacy when standard models were unavailable?",{"text":72,"@type":64},"The study describes flexible designs that include patient-derived cells, disease- and tumor-specific cell models, and the use of similar disease animal models and normal animals. Biomarkers were also used for evaluation and as endpoints in some clinical trials.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342377,1790650595,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Yokoshiki and Arato  \nOrphanet Journal of Rare Diseases (2024) 19:5 [https://doi.org/10.1186/s13023-023-03000-0](https://doi.org/10.1186/s13023-023-03000-0)  \nOrphanet Journal of Rare Diseases  \n RESEARCH Open Access  \nImplementation status of pharmacological   studies in the development of orphan drugs  \nSaki Yokoshiki1,2 and Teruyo Arato1,2*  \nAbstract  \nBackground The nonclinical as well as clinical development of orphan drugs is difficult, owing to unknown pathophysiology and the absence of animal models. Both, the U. S. Food and Drug Administration (FDA) Guidance and European Medicines Agency (EMA) Guidelines, for orphan drug development describe non-clinical studies, but lack specific information, such as animal species and study design. Against this background, this study aimed to elucidate efficient methods for evaluating nonclinical efficacy based on a review report of orphan drugs approved in Japan. Results A total of 184 orphan drugs, including 84 anticancer and 100 non-anticancer drugs, approved in Japan from January 2010 to December 2019 were investigated. Some anticancer drugs progressed to clinical development without distinct efficacy data in nonclinical studies. Patient-derived cells have been used for some drugs due to a lack of established cell lines. Cells used for non-clinical studies were devised for drugs indicated for cancers resistant to prior therapies, tumours with specific amino acid mutations in the target molecules, and solid tumours with specific biomarkers. For some non-anticancer drugs, similar disease animal models and normal animals were used for evaluation, since animal models did not exist. Biomarkers have been used specifically for evaluation in normal animals and as endpoints in some clinical trials.  \nConclusions It was possible to evaluate drug efficacy by flexibly designing nonclinical studies according to disease characteristics for potentials orphan drugs. These approaches, which are not described in detail in the EMA Guideline or FDA Guidance, may thus lead to approval.  \nKeywords Rare diseases, Orphan drugs, Non-clinical studies, Cell lines, Animal models, Biomarkers, Guidance  \nBackground  \nRecent advances in medicine have elucidated the pathophysiology of rare diseases, wherein identifying the aetiology and diagnosis are difficult, and new treatments have been developed. Drug development by pharmaceutical companies had focused on commonly occurring  \n*Correspondence:  \nTeruyo Arato[arato@med.hokudai.ac.jp](arato@med.hokudai.ac.jp)  \n1 Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan  \n2 Institute of Health Science Innovation for Medical Care (HELIOS), Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan  \ndiseases; however, the rare diseases have recently gained considerable attention [1, 2]. Among the new drugs approved by the U.S. Food and Drug Administration (FDA) in 2020 and 2021, 60% are for rare diseases [3]. Currently, many of the drugs developed in academia are also for rare diseases. However, for developing orphan drugs, it is difficult to apply the clinical trial design used in general drug development because of the small number of patients. It is also difficult to evaluate drug efficacy in nonclinical studies, since the pathophysiology has not been fully elucidated [4].  \nCurrently, no guidelines exist for orphan drug development in Japan. In 2006, the European Medicines Agency (EMA) issued Guideline on Clinical Trials in Small Populations [5]. The FDA also issued Rare Diseases: Common  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or oth","cbCaibqfUijS9OCA","https://ap.wps.com/l/cbCaibqfUijS9OCA","pdf",1292463,12,"English","# Abstract\n# Background\n# Results\n# Conclusions","[{\"question\":\"Why is developing orphan drugs difficult in nonclinical and clinical stages?\",\"answer\":\"Nonclinical and clinical development is difficult because disease mechanisms are not well understood and established animal models are often absent. Existing guidance also lacks specific details such as animal species and study design.\"},{\"question\":\"How many orphan drugs were investigated, and what was the study period?\",\"answer\":\"The review investigated 184 orphan drugs approved in Japan, covering January 2010 to December 2019.\"},{\"question\":\"What approaches were used to evaluate nonclinical efficacy when standard models were unavailable?\",\"answer\":\"The study describes flexible designs that include patient-derived cells, disease- and tumor-specific cell models, and the use of similar disease animal models and normal animals. Biomarkers were also used for evaluation and as endpoints in some clinical trials.\"}]","Implementation status of pharmacological studies in the development of orphan drugs | PDF",1790046343,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/300e0c5eb8e74b3a624a043c2e4a576f.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b864a3a242a0b7dda8518a0a95a4e249.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68863767782c7327dffa985b7bec7e48.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5eb461d930392d8d3292139b831c421d.webp",980,1301]